Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

News Conference News ESC 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Michael O'Riordan

September 09, 2024

News Daily News

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

Michael O'Riordan

January 03, 2024

News Conference News EuroPCR 2023

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

Michael O'Riordan

May 18, 2023

News Conference News

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

Shelley Wood

August 30, 2021

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

News Daily News

More Acute Stent Thrombosis With Synergy Stent in Bern PCI Registry

Michael O'Riordan

August 14, 2019

News Daily News

FDA Approves Orsiro Ultrathin-Strut Stent for CAD

Michael O'Riordan

February 22, 2019

News Conference News TCT 2018

Resolute Onyx Fares Well Against Thin-Strut Orsiro Stent in BIONYX All-Comers Study

Michael O'Riordan

September 22, 2018

News Conference News EuroPCR 2018

Chinese Firehawk Stent Performs Well Against Xience in All-Comers Study

Michael O'Riordan

May 29, 2018

News Conference News EuroPCR 2018

Balking at Bulk: SORT-OUT VIII Hints at Clinical Edge for Thinner-Strut Stents

Shelley Wood

May 24, 2018

News Industry News

Cordis and Medinol Announce FDA Approval of the Innovative EluNIR Drug-Eluting Stent System

November 30, 2017

News Daily News

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Michael O'Riordan

October 17, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Conference News EuroPCR 2017

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Michael O'Riordan

May 15, 2017

News Conference News TCT 2016

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Shelley Wood

November 07, 2016

News Conference News TCT 2016

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

TCT Daily Staff

October 30, 2016

News Daily News

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Michael O'Riordan

July 05, 2016

News Industry News

Micell Technologies Announces First Patient Enrolled in Registration Trial of MiStent SES in China

July 22, 2015

News Daily News

More Long-term Cardiac Mortality with First-Generation DES vs. BMS for STEMI

July 24, 2013

Advertisement

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

More Acute Stent Thrombosis With Synergy Stent in Bern PCI Registry

FDA Approves Orsiro Ultrathin-Strut Stent for CAD

Resolute Onyx Fares Well Against Thin-Strut Orsiro Stent in BIONYX All-Comers Study

Chinese Firehawk Stent Performs Well Against Xience in All-Comers Study

Balking at Bulk: SORT-OUT VIII Hints at Clinical Edge for Thinner-Strut Stents

Cordis and Medinol Announce FDA Approval of the Innovative EluNIR Drug-Eluting Stent System

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Micell Technologies Announces First Patient Enrolled in Registration Trial of MiStent SES in China

More Long-term Cardiac Mortality with First-Generation DES vs. BMS for STEMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content